Free Trial
OTCMKTS:ENZN

Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

Enzon Pharmaceuticals logo
$0.08 0.00 (-0.36%)
As of 05/23/2025 01:24 PM Eastern

About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)

Key Stats

Today's Range
$0.08
$0.08
50-Day Range
$0.08
$0.12
52-Week Range
$0.07
$0.24
Volume
50,000 shs
Average Volume
55,476 shs
Market Capitalization
$6.17 million
P/E Ratio
8.33
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Receive ENZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENZN Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Enzon Pharmaceuticals Inc ENZN
OKYO Pharma Limited (OK10.F)
Enzon Stock Hits New 52-Week Low (ENZN)
Ibnsina Pharma Co (ISPH)
See More Headlines

ENZN Stock Analysis - Frequently Asked Questions

Enzon Pharmaceuticals' stock was trading at $0.1561 on January 1st, 2025. Since then, ENZN shares have decreased by 46.7% and is now trading at $0.0832.
View the best growth stocks for 2025 here
.

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) posted its quarterly earnings data on Friday, May, 9th. The biotechnology company reported ($0.01) earnings per share for the quarter.

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX).

Company Calendar

Last Earnings
5/09/2025
Today
5/25/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:ENZN
Previous Symbol
NASDAQ:ENZN
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
8.33
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.37 million
Pretax Margin
5,103.85%

Debt

Sales & Book Value

Annual Sales
$30,000.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
73,918,000
Market Cap
$6.17 million
Optionable
Not Optionable
Beta
0.25

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (OTCMKTS:ENZN) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners